SUNSHINE NOHO and Youjia Biopharma Forge Strategic Alliance to Co-Develop Innovative Antibody-Oligonucleotide Conjugate (AOC) Therapeutics
YOUJIA BIO
Nucleic Acid Drug Developer
SunNovo
Drug Research and Development Service Provider
SunNovo × YOUJIA BIO
Antibody/Peptide Nucleic Acid Conjugation Technology Platform
SunNovo and Youjia (Hangzhou) Biomedical Technology Co., Ltd. ("YOUJIA BIO") Officially Sign Project Cooperation Agreement and Strategic Cooperation Agreement to Jointly Develop an Innovative Antibody Oligonucleotide Conjugate (AOC) New Drug
The core of the collaboration between SunNovo and YOUJIA BIO lies in the joint development of an innovative AOC drug. By utilizing the AOC technology platform, they will ingeniously combine antibodies with siRNA drugs to achieve precise regulation of target molecules, aiming for superior therapeutic effects. This innovative research approach is expected not only to offer patients more precise and efficient treatment options but also to drive a groundbreaking advancement in drug development within this field.
Technology Empowerment: AOC Platform Leads the Revolution in Metabolic Regulation
AOC technology combines the targeted delivery capability of antibodies with the gene silencing effect of siRNA through chemical coupling, enabling precise regulation of key targets in fat metabolism and muscle synthesis.
Compared with traditional therapies, this technology has three breakthrough advantages:
Strong tissue specificity:Antibody carriers break through biological barriers, achieving highly efficient delivery to extrahepatic tissues (such as fat and muscle);
Long-acting Regulation:A single dose can achieve weeks-long sustained gene silencing, improving patient compliance;
High Safety:Chemical modification technology reduces off-target risks and minimizes systemic side effects.
SunNovo and YOUJIA BIO will engage in in-depth cooperation across various stages, including drug discovery, research and development, clinical trials, and commercial promotion. Both parties will fully leverage their respective technological advantages and resources to jointly ensure the smooth progress of the projects, bringing benefits to patients worldwide.
This collaboration not only marks the deep integration of SunNovo and YOUJIA BIO in the field of innovative drug development, but also heralds the broad prospects for the two companies to introduce new therapeutic drugs to the global market. By combining AOC technology with nucleic acid drug technology, both parties will jointly explore new pathways in the technological domain, bringing more precise and efficient treatment options to patients worldwide, and together writing a new chapter in the research and development of innovative drugs.
About YOUJIA BIO
Youjia (Hangzhou) Biomedical Technology Co., Ltd. ("YOUJIA BIO") is a leader in the development of innovative nucleic acid technologies in China, co-founded in 2019 by returned overseas postdoctoral researchers and seasoned industry experts. The company is located in the Xiaoshan Economic and Technological Development Zone in Hangzhou, with 40 employees and nearly 1,500 square meters of R&D laboratory space. Committed to the vision of ensuring that diseases have effective treatments, the company strives to provide innovative therapeutic solutions driven by clinical needs.
YOUJIA BIO has established the SEQUAD nucleic acid drug full-process development platform, which can rapidly advance the development of nucleic acid drugs and the industrialization of nucleic acid technology products. YOUJIA BIO is a 5213 talent project in Xiaoshan District, and has been approved as a Hangzhou-level research and development center, as well as a Zhejiang Province specialized, refined, distinctive, and innovative small and medium-sized enterprise.
About SunNovo
Beijing Sunshine Nohe Drug Research Co., Ltd. (STAR Market Code: 688621) is a comprehensive enterprise focused on innovative drug research and development, establishing a "three-in-one" business ecosystem of "R&D services + pipeline cultivation + new quality industrial chain." Relying on an international technical team and an intelligent R&D system, the company provides full-cycle solutions from drug discovery to industrialization for global biopharmaceutical enterprises.
Currently, SunNovo has dozens of varieties under research, covering multiple therapeutic areas such as autoimmune diseases, pain management, cardiovascular, central nervous system, oncology, metabolism, and respiratory. The company adheres to the dual-driven strategy of "independent innovation + technology transfer". By building an international standard R&D platform and a comprehensive industrial collaboration network, it helps pharmaceutical companies in China break through technical barriers, accelerate the process of import substitution, and actively promote global innovation layout.